Trade

with

Transgenomic Inc
(NASDAQ: TBIO)
AdChoices
3.45
+0.13
+3.92%
After Hours :
-
-
-

Open

3.49

Previous Close

3.32

Volume (Avg)

36.72k (27.67k)

Day's Range

3.10-3.60

52Wk Range

0.3150-5.90

Market Cap.

24.41M

Dividend Rate ( Yield )

-

Beta

0.61

Shares Outstanding

7.35M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Diagnostics & Research
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 27.54M

    • Net Income

    • -15.99M

    • Market Cap.

    • 24.41M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -71.49

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.61

    • Forward P/E

    • -1.61

    • Price/Sales

    • 0.98

    • Price/Book Value

    • 2.46

    • Price/Cash flow

    • -2.53

      • EBITDA

      • -13.01M

      • Return on Capital %

      • -52.52

      • Return on Equity %

      • -118.21

      • Return on Assets %

      • -52.52

      • Book Value/Share

      • 1.40

      • Shares Outstanding

      • 7.35M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 10.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -2.44

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -7.40

          • 21.91

          • Net Income

            YTD/YTD (last year)

          • -

          • -5.55

          • Net Income

            Q/Q (last year)

          • -

          • 0.44

          • Sales (Revenue)

            5-Year Annual Average

          • 2.80

          • 47.82

          • Net Income

            5-Year Annual Average

          • -

          • 4.98

          • Dividends

            5-Year Annual Average

          • -

          • 5.31

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 43.10

            • 42.70

            • Pre-Tax Margin

            • -66.54

            • 11.63

            • Net Profit Margin

            • -71.49

            • 9.55

            • Average Gross Margin

              5-Year Annual Average

            • 50.40

            • 43.76

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -27.60

            • 11.34

            • Average Net Profit Margin

              5-Year Annual Average

            • -29.50

            • 52.13B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.60

              • 0.62

              • Current Ratio

              • 1.37

              • 1.23

              • Quick Ratio

              • 0.87

              • 0.76

              • Interest Coverage

              • -

              • 5.98

              • Leverage Ratio

              • 3.02

              • 2.16

              • Book Value/Share

              • 1.40

              • 14.94

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.37

                • 33.22

                • P/E Ratio 5-Year High

                • -8.82

                • 325.07

                • P/E Ratio 5-Year Low

                • -1.03

                • 154.73

                • Price/Sales Ratio

                • 0.98

                • 2.34

                • Price/Book Value

                • 2.46

                • 3.04

                • Price/Cash Flow Ratio

                • -2.53

                • 19.08

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -118.21

                    (-64.00)

                  • 9.34

                    (9.80)

                  • Return on Assets %

                    (5-Year Average)

                  • -52.52

                    (-26.10)

                  • 4.63

                    (5.44)

                  • Return on Capital %

                    (5-Year Average)

                  • -80.08

                    (-39.70)

                  • 5.73

                    (6.77)

                  • Income/Employee

                  • -

                  • 17.17k

                  • Inventory Turnover

                  • 3.50

                  • 5.07

                  • Asset Turnover

                  • 0.73

                  • 0.48

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -15.76M
                  Operating Margin
                  -57.21
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.53
                  Ownership

                  Institutional Ownership

                  44.17%

                  Top 10 Institutions

                  42.89%

                  Mutual Fund Ownership

                  3.87%

                  Float

                  73.36%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    282,740

                  • 0.00

                  • 3.83

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    2,758

                  • 0.00

                  • 0.04

                  • Marketocracy Masters 100 Fund

                  •  

                    800

                  • 0.00

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Leviticus Partners L P

                  •  

                    5,000,000

                  • +14.89%

                  • 5.67

                  • Perceptive Advisors LLC

                  •  

                    183,957

                  • 0.00%

                  • 2.81

                  • White Pine Capital LLC

                  •  

                    154,726

                  • +19.27%

                  • 2.36

                  • Potomac Capital Management, Inc.

                  •  

                    150,000

                  • 0.00%

                  • 2.04

                  • Kopp Investment Advisors LLC

                  •  

                    83,502

                  • -90.53%

                  • 1.14

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Diagnostics & Research

                  Type

                  Distressed

                  Style

                  Small Core

                  Transgenomic Inc was incorporated in Delaware on March 6, 1997. The Company is a biotechnology company advancing personalized medicine in the detection and treatment of cancer and inherited diseases through its proprietary molecular ...moretechnologies and world-class clinical and research services. Its operations are organized and reviewed by management along its product lines and presented in the following two complementary business segments: Laboratory Services and Genetic Assays and Platform. In Laboratory Services: its laboratories specialize in genetic testing for cardiology, neurology, mitochondrial disorders and oncology. Its Patient Testing laboratories located in New Haven, Connecticut and Omaha, Nebraska are certified under the Clinical Laboratory Improvement Amendment (“CLIA”) as high complexit...morey laboratories and its Omaha facility is also accredited by the College of American Pathologists (“CAP”). Its laboratories employ genomic testing service technologies, including ICE COLD-PCR technology. ICE COLD-PCR is a proprietary platform technology that can be run in any laboratory with standard PCR technology and that enables detection of multiple unknown mutations from virtually any sample type including tissue biopsies, blood, cell-free DNA (“cfDNA”) and circulating tumor cells (“CTCs”) at levels greater than 1,000-fold higher than standard DNA sequencing techniques. In enetic Assays and Platforms: its proprietary product is the WAVE System, which has applicability to genetic variation detection in both molecular genetic research and molecular diagnostics. It also distributes bioinstruments produced by other manufacturers (“OEM Equipment”) through its sales and distribution network. The Company also distributes bioinstruments produced by other manufacturers (‘OEM Equipment’) through its sales and distribution network. Service contracts to maintain installed systems are sold and supported by its technical support personnel. The installed WAVE base and some OEM Equipment platforms generate a demand for consumables that are required for the continued operation of the bioinstruments. It develops, manufactures and sells these consumable products. In addition, it manufactures and sells consumable products that can be used on multiple, independent platforms. These products include SURVEYOR Nuclease and a range of chromatography columns. Competitors in these areas, among others, include Applied Biosystems, Qiagen, Roche, Sequenom and Illumina. Competition for some of its non-WAVE consumable products comes from numerous well-diversified life sciences reagent providers, including, among others, Invitrogen, Qiagen, Roche, Stratagene and Promega. The Company is subject to a variety of federal, state and municipal environmental and safety laws based on its use of hazardous materials in both manufacturing and research and development operations.lessless

                  Key People

                  Mr. Paul Kinnon

                  CEO/President/Director

                  Dr. Rodney S. Markin,M.D.,PhD

                  Chairman of the Board/Director

                  Mark P. Colonnese

                  CFO/Chief Accounting Officer/Executive VP

                  Mr. Rob Patzig

                  Director

                  Mr. Doit Koppler, II

                  Director

                  • Transgenomic Inc

                  • 12325 Emmet Street

                  • Omaha, NE 68164

                  • USA.Map

                  • Phone: +1 402 452-5400

                  • Fax: +1 402 452-5401

                  • transgenomic.com

                  Incorporated

                  1997

                  Employees

                  171

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: